RNA Interference siRNA Patents

RNA interference (RNAi/siRNA) patents cover siRNA-sequence and design innovations; chemical-modification innovations; conjugate and nanoparticle-delivery innovations; and foundational RNAi-mechanism patents — with IP held by the RNAi-therapeutics leader, conjugate-platform companies, and the academic discoverers. MAJOR RNAi/siRNA PATENT HOLDERS: ALNYLAM (the dominant RNAi-therapeutics estate): the first approved RNAi drugs — patisiran (Onpattro, LNP-delivered, hereditary ATTR amyloidosis), givosiran (Givlaari), lumasiran (Oxlumo), vutrisiran (Amvuttra), and inclisiran (Leqvio, partnered with Novartis, for LDL cholesterol) — plus the Enhanced Stabilization Chemistry (ESC) GalNAc-conjugate platform for subcutaneous hepatocyte delivery, and a deep foundational portfolio. ARROWHEAD PHARMACEUTICALS: the TRiM (Targeted RNAi Molecule) platform and ligand-conjugate delivery (liver and extrahepatic — lung). DICERNA (Novo Nordisk): the GalXC GalNAc-conjugate platform. SILENCE THERAPEUTICS: the mRNAi GOLD GalNAc platform. OTHERS: Ionis (primarily antisense but also siRNA), Quark, and the foundational academic holders — Andrew Fire and Craig Mello (the Nobel-winning discovery of RNAi, basic patents), Thomas Tuschl (siRNA function in mammalian cells — the 'Tuschl patents,' heavily litigated/licensed), and Kreutzer-Limmer. GalNAc-conjugate delivery and chemical-modification chemistry are the core modern RNAi patent domains.

siRNA-sequence and duplex-design innovations; chemical-modification innovations; stabilization and off-target-reduction innovations; and dosing/silencing innovations represent core RNAi patent domains — and chemical modification is what turned siRNA from a fragile molecule into a durable drug. SEQUENCE / DESIGN PATENTS: the siRNA duplex targeting a specific gene transcript (a ~19–23-nucleotide guide/antisense + passenger/sense strand), guide-strand selection and seed-region design, and the specific sequence as composition-of-matter against a target mRNA. CHEMICAL-MODIFICATION PATENTS: 2′-O-methyl and 2′-fluoro ribose modifications (nuclease resistance), phosphorothioate backbone linkages (stability, pharmacokinetics), glycol-nucleic-acid and other modified nucleotides, and specific modification PATTERNS across the duplex (Alnylam's Standard Template Chemistry STC and Enhanced Stabilization Chemistry ESC are patented modification patterns that dramatically extend duration and potency). STABILIZATION / OFF-TARGET PATENTS: seed-pairing destabilization (e.g. glycol-modified nucleotide at position 7) to reduce off-target effects, thermodynamic asymmetry for correct strand loading into RISC, and immunostimulation reduction. The specific chemical-modification pattern, more than the bare sequence, is often the most valuable and defensible siRNA IP because it determines potency, duration (enabling quarterly/biannual dosing), and safety.

GalNAc-conjugate and targeted-ligand delivery innovations; lipid-nanoparticle delivery innovations; extrahepatic-delivery innovations; and foundational RNAi-mechanism patents represent additional siRNA patent domains — and delivery (getting siRNA into the right cell) has been the central RNAi challenge. GalNAc-CONJUGATE PATENTS: tri-antennary N-acetylgalactosamine GalNAc ligands conjugated to the siRNA that bind the asialoglycoprotein receptor ASGPR on hepatocytes, enabling simple subcutaneous dosing and efficient liver uptake (the breakthrough behind givosiran/inclisiran) — including linker chemistry, valency, and conjugation site. LNP-DELIVERY PATENTS: lipid nanoparticles (ionizable lipid, like the chemistry behind patisiran) for systemic/IV delivery to the liver, shared lineage with mRNA-vaccine LNPs (MC3/DLin-MC3-DMA — Alnylam/Acuitas heritage). EXTRAHEPATIC PATENTS: conjugates and formulations for delivery beyond the liver (CNS intrathecal, lung, muscle, eye) — the major open frontier, since most approved RNAi is liver-restricted. MECHANISM PATENTS: foundational RNAi-pathway patents (Fire-Mello discovery, Tuschl mammalian siRNA, Dicer processing, RISC/Argonaute loading) — though these foundational patents are aging and some have expired or been litigated. GalNAc-conjugate delivery and the push to extrahepatic tissues are the highest-value RNAi delivery IP.

RNAi startup IP strategy must navigate Alnylam's dominant and deep RNAi estate (GalNAc, chemical modification, many targets), foundational Tuschl/Fire-Mello mechanism patents (some aging/expired, historically heavily licensed), Arrowhead/Dicerna/Silence conjugate platforms, lipid-nanoparticle IP (shared with mRNA, including Arbutus/Genevant), and a landscape where the durable asset is a specific siRNA sequence + chemical-modification pattern against a target, plus a delivery solution; understand that liver (GalNAc) delivery is well-covered by Alnylam and others, that the modification pattern is often more defensible than the bare sequence, and that extrahepatic delivery is the open frontier; identify whitespace in extrahepatic-targeting ligands/conjugates (CNS, lung, muscle), novel modification chemistries, and novel targets. RNAi STARTUP IP STRATEGY: SEQUENCE + MODIFICATION PATTERN + DELIVERY ARE THE IP: patent the specific siRNA (guide/passenger sequence against a target) AND its chemical-modification pattern (2'-OMe/2'-F/phosphorothioate arrangement) — the pattern drives potency/duration/safety and is often the stronger claim; GalNAc/LIVER IS CROWDED — EXTRAHEPATIC DELIVERY IS HIGHEST-VALUE WHITESPACE: Alnylam/Dicerna/Silence cover GalNAc-hepatocyte delivery densely; the open frontier and biggest prize is conjugates/formulations that reach CNS, lung, muscle, and eye; FOUNDATIONAL MECHANISM PATENTS ARE AGING — BUT CHECK FTO: Tuschl/Fire-Mello are old and some expired, but verify freedom-to-operate on chemistry and delivery (Alnylam, Arbutus/Genevant LNP); NOVEL MODIFICATION CHEMISTRY IS PATENTABLE: new nucleotide modifications or patterns that improve duration/off-target are durable IP; WHEN TO PATENT: NOVEL siRNA/DELIVERY WITH MEASURED SILENCING: file once a candidate shows measured results (target knockdown % + duration + off-target profile + tissue delivery + tolerability) — measured silencing potency, duration of effect, tissue specificity, and off-target/safety are the critical RNAi IP metrics; KEY FTO CHECKLIST: Alnylam GalNAc ESC/STC chemical-modification ASGPR conjugate; patisiran LNP ionizable-lipid (Arbutus/Genevant); Arrowhead TRiM, Dicerna GalXC, Silence GOLD conjugates; Tuschl mammalian siRNA; Fire-Mello RNAi mechanism; 2'-OMe/2'-F/phosphorothioate modification patterns; seed-destabilization off-target reduction; extrahepatic CNS/lung ligand-conjugate; composition-of-matter siRNA sequence.